patent settlement

Moderna settles $950M patent dispute with Arbutus and Genevant, clearing legal uncertainty. Stock surges 8.85% as company targets 2028 breakeven with $4.5-5B cash by 2026.

Esperion secures fifth settlement with generic drugmaker Alkem, extending market exclusivity for cholesterol drugs NEXLETOL and NEXLIZET through April 2040.